{"id":249786,"date":"2023-09-26T00:00:00","date_gmt":"2023-09-26T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinop0001-2023-biopharma-retinal-vein-occlusion-executive-insights\/"},"modified":"2026-03-31T10:32:08","modified_gmt":"2026-03-31T10:32:08","slug":"exinop0001-2023-biopharma-retinal-vein-occlusion-executive-insights-executive-insights-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinop0001-2023-biopharma-retinal-vein-occlusion-executive-insights-executive-insights-us\/","title":{"rendered":"Retinal Vein Occlusion &#8211; Executive Insights &#8211; Executive Insights (US)"},"content":{"rendered":"<p>Retinal vein occlusion (<abbr title=\"retinal vein occlusion\">RVO<\/abbr>) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having branch, central, or hemi-retinal vein occlusion (<abbr title=\"branched retinal vein occlusion\">BRVO<\/abbr>, <abbr title=\"central retinal vein occlusion\">CRVO<\/abbr>, HRVO, respectively). Because <abbr title=\"retinal vein occlusion\">RVO<\/abbr>s compromise venous return from the retinal circulation, they may trigger retinal ischemia, macular edema, and\/or neovascularization. The standards of care for macular edema following <abbr title=\"retinal vein occlusion\">RVO<\/abbr> include the anti-<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr>s Eylea (Regeneron \/ Bayer), Lucentis (Roche \/ Genentech), and off-label Avastin (Roche \/ Genentech) and the corticosteroid implant Ozurdex (AbbVie). Notably, Roche \/ Chugai expect to submit an expanded application for Vabysmo for <abbr title=\"branched retinal vein occlusion\">BRVO<\/abbr> and <abbr title=\"central retinal vein occlusion\">CRVO<\/abbr> in the United States and Europe in 2023. Although the number of therapies in development for <abbr title=\"retinal vein occlusion\">RVO<\/abbr> is small, commercial opportunity remains for therapies with a longer dosing duration, greater efficacy, and\/or a convenient route of administration.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What diagnostic tests are used to characterize <abbr title=\"retinal vein occlusion\">RVO<\/abbr> patients, and how are different patient subtypes treated?<\/li>\n<li>What are the physician-perceived advantages and disadvantages of current therapies?<\/li>\n<li>What are the key areas of unmet need and opportunity in the <abbr title=\"retinal vein occlusion\">RVO<\/abbr> market?<\/li>\n<li>What are the key strengths, weaknesses, drivers, and constraints of the <abbr title=\"retinal vein occlusion\">RVO<\/abbr> market?<\/li>\n<li>What influence does each major player hold over the <abbr title=\"retinal vein occlusion\">RVO<\/abbr> market?<\/li>\n<li>What are the competitive landscape and the expected future influence of key emerging therapies, including Roche \/ Chugai\u2019s Vabysmo, in the treatment of <abbr title=\"retinal vein occlusion\">RVO<\/abbr>?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>PRIMARY RESEARCH<\/strong><\/p>\n<p>3 <abbr title=\"key opinion leader\">KOL<\/abbr> interviews in July 2023<\/p>\n<p><strong>KEY COMPANIES COVERED <\/strong><\/p>\n<p>Regeneron, Roche\/Genentech, AbbVie (legacy Allergan), Biogen, Coherus, Annexin, 3T Ophthalmics<\/p>\n<p><strong>KEY DRUGS COVERED <\/strong>ANXV,<strong>\u00a0<\/strong>Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Ozurdex, ONS-5010 (Lytenava), RG-7921<\/p>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.<\/p>\n","protected":false},"template":"","class_list":["post-249786","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ophthalmology","biopharma-therapy-areas-retinal-vein-occlusion","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249786\/revisions"}],"predecessor-version":[{"id":281350,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249786\/revisions\/281350"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}